若生智能
Drug Database
DO

doxorubicin hydrochloride (Libod / Libaoduo)

✓ Approved

Shanghai Fudan-Zhangjiang · TOP2A · 小分子

什么是 doxorubicin hydrochloride？

doxorubicin hydrochloride 是一种小分子，由Shanghai Fudan-Zhangjiang研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Libod, Libaoduo
公司Shanghai Fudan-Zhangjiang
药物类别小分子
分子靶点TOP2A
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Shanghai Fudan-Zhangjiang

作用机制

分子靶点

doxorubicin hydrochloride 作用于 1 个分子靶点：

TOP2ADNA topoisomerase II alpha (TOP2alpha, TOPIIA)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

doxorubicin hydrochloride 针对 4 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Kaposi's sarcoma✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved

相关研究文献

PubMedResearch in veterinary science2026-08-04

Pharmacokinetics of oral and subcutaneous administration of free and liposomal levamisole in goats.

Susar Hasan H, Çelebi Murat M, Özüiçli Mehmet M, Çelebi Çağla Ç et al.

New drug formulations are needed to prevent antiparasitic resistance in goats. Liposomes are one of the most commonly used drug delivery systems for this purpose. This study aims to determine the pharmacokinetics of free and liposomal levamisole in goats after single oral (O) and subcutaneous (SC) administrations at a dose of 7.5 mg/kg. It was hypothesized that liposomal levamisole in goats may improve its pharmacokinetic profile by increasing systemic exposure and improving drug bioavailability compared to free levamisole. The study developed a levamisole liposome and investigated relevant parameters: particle size, zeta potential, polydispersity index, encapsulation efficiency, pH, and morphology. Blood samples were collected using heparinized tubes from the jugular vein through a cannula at 0 (control), 0.083, 0.167, 0.25, 0.5, 1, 2, 4, 8, 12, 18, and 24 h. Free and liposomal levamisole plasma concentrations were measured using high-performance liquid chromatography ultraviolet (HPLC-UV). The developed levamisole liposomes were characterized by an average PS of 204.3 ± 3.7 nm, a PDI of 0.251 ± 0.033, a ZP of -16.3 ± 0.5 mV, and an EE of 76.08 ± 0.03%. Liposomal formulations showed significantly higher values than free formulations in terms of λz (O: 91.3%↑, FLO: 0.046 ± 0.006 h-1, LLO: 0.088 ± 0.01 h-1; SC: 9.2%↓, FLSC: 0.076 ± 0.021 h-1, LLSC: 0.069 ± 0.018 h-1), Cmax (O: 70.5%↑, FLO: 1211.219 ± 410.407 ng/mL, LLO: 2064.533 ± 412.011 ng/mL; SC: 14.1%↑, FLSC: 2050.623 ± 186.165 ng/mL, LLSC: 2340.168 ± 348.122 ng/mL), Clast (O: 56.0%↑, FLO: 77.538 ± 9.053 ng/mL, LLO: 120.969 ± 57.718 ng/mL; SC: 85.4%↑, FLSC: 112.795 ± 30.262 ng/mL, LLSC: 209.142 ± 45.257 ng/mL), AUC0-t (O: 148%↑, FLO: 4134.794 ± 745.011 h*ng/mL, LLO: 10261.449 ± 3915.247 h*ng/mL; SC: 47%↑, FLSC: 9922.304 ± 3223.356 h*ng/mL, LLSC: 14575.461 ± 3677.068 h*ng/mL), and AUC0-∞ (O: 98%↑, FLO: 5876.493 ± 1047.383 h*ng/mL, LLO: 11653.385 ± 4530.480 h*ng/mL; SC: 54%↑, FLSC: 11498.826 ± 3513.92 h*ng/mL, LLSC: 17728.218 ± 3361.133 h*ng/mL) parameters. In terms of route of administration, subcutaneous administration significantly increased Cmax, Clast, AUC0-t, and AUC0-∞ values. In oral administration, the t1/2 (48.6%↓, FLO: 15.463 ± 2.242 h, LLO: 7.956 ± 0.880 h) and ClT (45.3%↓, FLO: 1.310 ± 0.232 L/h/kg, LLO: 0.717 ± 0.235 L/h/kg) values of the drug were higher in the free formulation. The interaction between formulation and route of administration was significant for the λz, t1/2, and Vd/F parameters. Subcutaneous administration yielded enhanced pharmacokinetic performance than oral administration for the liposomal formulation, specifically in Clast (73%↑, LLO: 120.969 ± 57.718 ng/mL, LLSC: 209.142 ± 45.257 ng/mL), AUC0-t (42%↑, LLO: 10261.449 ± 3915.247 h*ng/mL, LLSC: 14575.461 ± 3677.068 h*ng/mL), AUC0-∞ (52%↑, LLO: 11653.385 ± 4530.480 h*ng/mL, LLSC: 17728.218 ± 3361.133 h*ng/mL), Cmax (13%↑, LLO: 2064.533 ± 412.011 ng/mL, LLSC: 2340.168 ± 348.122 ng/mL), and ClT (66.5%↓, LLO: 0.717 ± 0.235 L/h/kg, LLSC: 0.439 ± 0.101 L/h/kg). As a result, it was concluded that liposomal levamisole may exhibit potentially improved efficacy than free levamisole in goats. Future study directions include investigating liposomal levamisole in different species to determine whether improved efficacy is consistent.

PMID 42546527
阅读全文 →
PubMedFujita medical journal2026-08-04

Evaluation of renal function in a patient with terminal rectal cancer who developed morphine hydrochloride-induced respiratory depression.

Uekuzu Yoshihiro Y, Usui Masanobu M, Futamura Akihiko A, Inagaki Takahiko T

A challenge in patients with terminal cancer is that serum creatinine-based estimates of renal function often deviate from true renal function because cachexia-related loss of muscle mass leads to abnormally low serum creatinine levels. Serum cystatin C is a useful marker of renal function in patients with decreased muscle mass; however, there are limited data on its use in patients with terminal cancer. In this study, we present a detailed assessment of renal function, incorporating muscle mass measurement by bioelectrical impedance analysis, in a patient with terminal rectal cancer who developed respiratory depression while receiving a stable dose of morphine hydrochloride injections.

PMID 42549366
阅读全文 →
PubMedNanoscale2026-08-04

A bidirectional pyroptosis regulation strategy to resolve cardiotoxicity-antitumor efficacy dilemma of doxorubicin.

Xu Hanying H, Zhang Yi Y, Guo Hao H, Shao Zhong Z et al.

Doxorubicin (DOX), a frontline chemotherapeutic agent, is severely limited by reactive oxygen species (ROS) overload-mediated cardiotoxicity involving multiple programmed cell death pathways, with pyroptosis validated as one major mechanism, whereas conventional cardioprotective interventions may compromise antitumor efficacy. Here, we report a selectively redox-responsive approach based on self-crosslinked lipoic acid nanoparticles (LANPs) that enables bidirectional pyroptosis regulation in cardiac vs. tumor tissues, achieving concurrent cardioprotection and antitumor sensitization during DOX therapy. In cardiomyocytes, LANPs degrade into the lipoic acid (LA)/dihydrolipoic acid (DHLA) pair, which exerts anti-oxidant activity to scavenge excessive ROS, thereby mitigating oxidative stress-associated pyroptosis and subsequent cardiac injury. In cancer cells with a relatively high reducing environment, LANP degradation predominantly yields DHLA, which promotes ROS accumulation, thereby enhancing pyroptosis-associated antitumor efficacy. In female BALB/c mouse models, LANPs afford cardioprotection comparable to dexrazoxane (DEX), the only clinically approved cardioprotective agent against DOX, while additionally alleviating systemic toxicity, particularly bone marrow suppression, an advantage not afforded by DEX. As expected, LANPs not only preserve but also potentiate DOX-induced antitumor efficacy. This study establishes LANPs as a promising adjuvant strategy for expanding the scope of chemotherapeutic applications beyond DOX.

PMID 42548175
阅读全文 →
PubMedHuman vaccines & immunotherapeutics2026-08-04

Parental preferences for immunization advisory clinic settings for children with special health care needs and associated factors in Shanghai: A cross-sectional study.

Feng Tianxing T, Xu Yaqing Y, Li Jingjing J, Ge Yanling Y et al.

Children with special health care needs (CSHCN) face persistent immunization inequity despite high overall childhood vaccination coverage. Immunization advisory clinics (IACs) have expanded in China, yet parental preferences for different IAC settings remain poorly understood. This cross-sectional survey was conducted at the IAC of Children's Hospital of Fudan University, Shanghai, between October and December 2023. Parents of CSHCN younger than 14 y with incomplete National Immunization Program schedules were invited. The primary outcome was parental preference for IAC setting (community clinic, general hospital, or children's hospital); the secondary outcome was preferred vaccination-assessment provider under discordant recommendations. Multinomial and binary logistic regression models identified associated factors, adjusted for child, parent, and vaccine-attitude covariates. Sensitivity analyses were stratified by medication status. Reporting followed the STROBE statement. Of 102 questionnaires, 101 were valid (99.0% response rate). 51.0% of parents preferred community clinics, 25.7% preferred children's hospitals, and 23.3% preferred general hospitals. Parent Attitudes about Childhood Vaccines (PACV) score was not independently associated with setting preference. Parents of girls were more likely to prefer general hospitals (adjusted RRR, 7.02; 95% CI, 1.50-32.77), whereas lower household income was associated with reduced preference for general hospitals (adjusted RRR, 0.14; 95% CI, 0.03-0.75). Sensitivity analyses yielded consistent findings. Parental preferences for IAC settings among CSHCN families are shaped by child and socioeconomic characteristics rather than by vaccine hesitancy alone. Hybrid hospital-community delivery models and standardized referral pathways may improve vaccination equity for medically complex children.

PMID 42547995
阅读全文 →
PubMedZhonghua bing li xue za zhi = Chinese journal of pathology2026-08-04

[Sweat gland carcinoma with neuroendocrine differentiation: a clinicopathological analysis of three cases].

Pan W Y WY, Deng M Y MY, Luan L J LJ, Zhou W W et al.

Objective: To investigate the clinicopathological features, immunophenotype, and molecular characteristics of sweat gland carcinoma with neuroendocrine differentiation (SCAND). Methods: Three cases of SCAND diagnosed at the Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China from June 2022 to June 2025 were collected. Hematoxylin-eosin (HE) staining and immunohistochemistry (EnVision method) were performed to characterize morphologic and immunophenotypic features. Next-generation sequencing (NGS) was utilized to explore their molecular pathological characteristics. Results: All three patients were male, aged 67, 63, and 48 years, respectively. The primary tumors presented as solitary nodules or masses located in the lower abdomen, anterior chest wall, or inguinal region, with a maximum diameter of 2.0, 1.3, and 1.8 cm, respectively. Histologically, the tumors were situated primarily within the dermis, invading the epidermis and subcutaneous tissue, with focal mucin production. The tumor cells were arranged in nests, cords, and sieve-like patterns, exhibiting mild to moderate atypia. The nuclei were round to oval with coarsely granular chromatin and relatively inconspicuous nucleoli, accompanied by eosinophilic cytoplasm. Mitotic figures were scarce. All cases were positive for CK7, GATA3, TRPS1, Ber-EP4, epithelial membrane antigen, estrogen receptor, progesterone receptor, and the neuroendocrine markers of synaptophysin and chromogranin A. The tumors were negative for p40 and HER2. The Ki-67 proliferation index ranged from 2% to 30%. Multiple class Ⅲ and Ⅳ variants were identified by NGS analysis in cases 1 and 2. In case 3, a class Ⅱ variant, specifically an SF3B1 missense mutation, was identified along with multiple class Ⅲ and Ⅳ variants. Additionally, multiple germline variants were detected in all three cases, while none of them were classified as pathogenic or likely pathogenic. The patients were followed up for 13, 37 and 155 months, respectively. Metastases were detected 6, 36, and 96 months after diagnosis. Case 2 showed local metastasis, while cases 1 and 3 developed multiple nodal and bone metastases. Conclusions: SCAND is a rare cutaneous adnexal neoplasm characterized by co-expression of sweat gland and neuroendocrine markers. Despite low-grade morphology, it follows a non-indolent clinical course warranting close clinical attention.

PMID 42547418
阅读全文 →
PubMedTropical animal health and production2026-08-04

Ractopamine under dietary protein adjustment improves growth performance and carcass traits of immunocastrated and surgically castrated pigs slaughtered 21 days after vaccination.

Araujo Diego Duran DD, Ferreira Matheus de Almeida MA, Rodrigues Lucas Alves LA, Lopes Idael Matheus Góes IMG et al.

The objective of this study was to evaluate the effects of immunocastration and ractopamine hydrochloride (RAC) supplementation on growth performance and carcass traits of male pigs slaughtered 21 days after the second immunization. Sixty-four pigs (Landrace × Large White, initial body weight 103.05 ± 0.67 kg) were individually tagged and randomly assigned to a 2 × 2 factorial arrangement in a completely randomized design, consisting of two castration methods (immunocastrated vs. surgically castrated) and two dietary RAC levels (0 or 10 ppm). No castration method × RAC interactions were observed for any variable (P > 0.05). Immunocastrated (IM) pigs exhibited 19.5% greater average daily gain (ADG) and 13% lower feed-to-gain ratio (FG) compared with surgically castrated (SC) pigs (P < 0.05). IM pigs also showed reduced backfat thickness across all measurement sites and greater lean meat percentage, whereas SC pigs had higher carcass yield (P < 0.05). Ractopamine supplementation under increased amino acid supply increased ADG by 13.6%, improved hot carcass weight by 3.1%, and reduced FG by 13% (P < 0.05). Overall, immunocastration improved growth performance and carcass leanness, while RAC supplementation increased average daily gain by 13.6%, confirming its additive effect under a shortened 21-day post-immunization interval. Immunization against GnRH combined with RAC feeding represents an effective strategy for producing heavy-weight finishing pigs with improved efficiency.

PMID 42550353
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多doxorubicin hydrochloride